News

The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead Sciences has rallied the S&P 500 Index over the past year, and analysts remain highly bullish about the stock’s growth prospects.

GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.

Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.

Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.

Gilead Sciences has delivered strong share price gains over the past five years, yet based on broad valuation checks it still screens as inexpensive relative to its fundamentals. For investors, the stock now sits in an interesting spot where a powerful HIV and oncology franchise is reflected in the price to some extent, but the broader valuation read still points to room for a more optimistic view than the market currently implies. Over the past 5 years, Gilead Sciences has returned about...

Gilead Sciences (GILD) is back in focus after the European Commission approved Trodelvy plus Keytruda for certain first line metastatic triple negative breast cancer patients, expanding the company’s oncology franchise in Europe. For investors tracking the bigger picture, Gilead Sciences’ 1 month share price return of 10.25% and year to date share price return of 21.78% point to firming momentum. The 1 year total shareholder return of 34.99% and 5 year total shareholder return of 145.70%...

Gilead Sciences (NasdaqGS:GILD) received expanded European Commission approval for Trodelvy in combination with Keytruda as a first-line treatment for metastatic triple-negative breast cancer across PD-L1 status in Europe. The decision establishes Trodelvy plus Keytruda as the first antibody-drug conjugate and immunotherapy combination approved for first-line metastatic TNBC across the European Union. The ruling broadens Trodelvy’s addressable patient population in Europe and further...

Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.

Vivace Therapeutics has appointed Craig Gibbs as President and CEO as the company prepares to advance its lead candidate, VT3989, into a pivotal Phase 3 registrational trial. The clinical-stage biopharmaceutical company also named Ellen Lubman as Chief Business and Strategy Officer and...

Its growth profile stands well above major sector peers.

These healthcare leaders are unlikely to suspend their dividend programs.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

The European Commission on Monday authorized Trodelvy combined with Merck’s (MRK) Keytruda for certain adults with previously untreated advanced or metastatic triple-negative breast cancer.

A buyback funded by one oncology drug is concentrating each holder's claim while the next franchise waits on a regulatory decision.

Gilead Sciences, Inc. (NASDAQ:GILD) produced an unusual earnings report in fiscal Q2 2026. Its commercial portfolio delivered double-digit growth, and yet the company posted one of the largest quarterly losses in its recent history. So where did the disconnect come from? It was created by more than $11 billion in acquired research and development expenses […]

Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to approximately $7.8 billion. The performance was primarily driven by continued growth across its HIV franchise, including Biktarvy and the newly launched Yeztugo. Gilead also raised its full-year product-sales guidance following the quarter. However, HIV products generated […]

Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion. Yet, the income statement tells a considerably less flattering story. Gilead […]

The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday’s blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company. Pfizer’s (NYSE:PFE) newer medicines are gaining traction, but that growth has yet to accelerate the wider business. Gilead (NASDAQ:GILD) is expanding faster, although its performance remains concentrated in […]

The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development.

In August 2026, Nucleai announced an ongoing translational research collaboration with Gilead Sciences, using AI-powered tissue analytics to support Gilead's global antibody-drug conjugate clinical development programs across multiple oncology indications. The partnership highlights how integrating AI-native computational pathology with clinical outcomes may help standardize biomarker assessment and refine precision medicine efforts in Gilead's oncology portfolio. Next, we'll examine how...

These stocks can be safe-haven investments to hide out in amid market turmoil.

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.

The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.